LOGIN  |  REGISTER

Latest Collaborations and Licensing Agreement News

Ginkgo Bioworks Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry

August 20
Last Trade: 12.55 0.79 6.72

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously...Read more


Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

August 20
Last Trade: 123.11 2.58 2.14

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications For U.S. media and investors only DUBLIN and COPENHAGEN, Denmark, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:...Read more


ANGLE Announces Collaboration with Myriad Genetics

August 20
Last Trade: 6.02 0.19 3.26

Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20, 2025 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has...Read more


Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

August 19
Last Trade: 0.04 0.001 2.44

New agreement brings innovative shock wave, tPEMF therapy, monitoring, and bleeding control solutions to more than 2,200 member clinics nationwide ANN ARBOR, MI / ACCESS Newswire / August 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, announced today a new strategic partnership with VerticalVet,...Read more


GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

August 18
Last Trade: 4.56 0.07 1.56

Until today, Ozempic® has not been available to eligible self-paying patients at this price SANTA MONICA, Calif. / Aug 18, 2025 / Business Wire / GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,...Read more


Elevance Health and National Association of Community Health Centers Partnership Integrates Food as Medicine With Primary Care

August 18
Last Trade: 316.55 6.95 2.24

Trained providers to screen, enroll eligible members to receive evidence-based nutrition and dietary services. INDIANAPOLIS / Aug 18, 2025 / Business Wire / Elevance Health and the National Association of Community Health Centers (NACHC) are proud to announce the integration of Food as Medicine (FAM) programming with primary care Community Health Centers (CHCs). This milestone - built on a shared commitment to whole health and...Read more


The Oncology Institute and Doctors Healthcare Plans Partner to Elevate Oncology Care Management in South Florida

August 18
Last Trade: 3.79 0.10 2.71

CERRITOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a national leader in value-based oncology care, is pleased to announce a strategic partnership with Doctors HealthCare Plans, a Medicare Advantage plan serving members across South Florida. The Oncology Institute will provide delegated utilization management services and clinical advisory support, helping Doctors HealthCare...Read more


OneMedNet initiates new Subscription Revenue model in partnership with Circle CVI

August 18
Last Trade: 0.78 0.01 1.30

MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in advanced cardiovascular imaging solutions. The collaboration reflects Circle CVI’s commitment to leveraging trusted, high-quality data to drive innovation in cardiac...Read more


Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

August 13
Last Trade: 20.22 0.16 0.80

Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment Sarepta sells at least $174 million of Arrowhead common stock for cash proceeds, Arrowhead will redeem $50 million of stock from Sarepta to prefund half of $100 million milestone payment due to Arrowhead CAMBRIDGE, Mass. / Aug 13, 2025 / Business Wire / Sarepta...Read more


Humana and DrFirst Partner on Innovation to Fill Gaps in Care, Improve Outcomes for Patients with Diabetes and Other Chronic Conditions

August 13
Last Trade: 299.51 5.04 1.71

Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va., Aug. 13, 2025 /PRNewswire/ -- Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, and health technology pioneer DrFirst today announced the launch of a program designed to close gaps in care for patients with chronic health conditions like diabetes and...Read more


BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

August 12
Last Trade: 0.37 0.00 0.00

Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA...Read more


Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology

August 12
Last Trade: 30.50 0.84 2.83

Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today announced that it has entered into an...Read more


Rakovina Therapeutics and NanoPalm Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

August 12
Last Trade: 0.51 0.01 2.00

KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery and NanoPalm Ltd.,...Read more


Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

August 7
Last Trade: 2.63 0.07 2.73

Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a...Read more


Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

August 6
Last Trade: 47.47 0.77 1.65

Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences’ leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard MADISON, Wis. / Aug 06, 2025 / Business Wire / Exact Sciences Corp....Read more


Actuate Therapeutics To Collaborate with Incyte and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

August 6
Last Trade: 8.36 0.69 9.00

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3...Read more


Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

August 6
Last Trade: 1.27 0.07 5.83

PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the...Read more


SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

August 5
Last Trade: 3.61 0.17 4.94

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for...Read more


American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

August 4
Last Trade: 61.40 0.12 0.20

Together, American Cancer Society and Guardant Health aim to remove barriers and increase cancer screening rates in communities that have historically limited access to preventive cancer care. SAN FRANCISCO / Aug 04, 2025 / Business Wire / The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision oncology company focused on improving access to cancer screening and...Read more


MaxCyte Signs Platform License Agreement with Adicet Bio

August 4
Last Trade: 1.42 0.00 0.00

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it...Read more


Medicus Pharma Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies to Develop Thermostable Infectious Disease Vaccines

August 4
Last Trade: 5.69 0.00 0.00

The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune...Read more


Arrowhead Pharmaceuticals Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

August 1
Last Trade: 21.33 0.58 2.80

Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with...Read more


Azenta Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

July 31
Last Trade: 31.55 1.71 5.73

BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance...Read more


Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

July 31
Last Trade: 25.60 0.35 1.39

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnostics BAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ --...Read more


MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

July 31
Last Trade: 1.42 0.00 0.00

MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a...Read more


Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

July 31
Last Trade: 124.79 5.14 4.30

WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand...Read more


Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

July 31
Last Trade: 47.47 0.77 1.65

Cologuard Plus™ Available In-Network August 2025 MADISON, Wis. / Jul 31, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage...Read more


Xenetic Biosciences Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

July 30
Last Trade: 3.03 0.21 7.45

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd....Read more


MiMedx Announces Strategic Collaboration with Vaporox

July 30
Last Trade: 7.31 0.28 3.98

Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the...Read more


NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

July 30
Last Trade: 1.70 -0.04 -2.30

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement. NetraMark, in collaboration...Read more


Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group

July 30
Last Trade: 414.68 7.59 1.86

License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in-class MASH treatment in a once-a-day, well-tolerated pill CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today...Read more


Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

July 30
Last Trade: 19.23 1.21 6.71

Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan  Viridian to receive an upfront payment of $70 million  Additionally, Viridian is eligible to receive up to an additional $315 million in development, regulatory, and commercial milestone payments as well as tiered royalties on net sales in Japan in the 20s to mid-30s percent  Collaboration combines Viridian’s potential...Read more


Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

July 30
Last Trade: 0.51 0.01 2.00

VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to highlight its long-standing collaboration with the University of British Columbia (UBC) and its affiliated Vancouver Prostate Centre (VPC), one of Canada’s leading cancer research...Read more


Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

July 30
Last Trade: 3.64 0.10 2.82

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology The deal terms include the purchase price of the site for around US$ 300 m in cash, and in...Read more


Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design

July 29
Last Trade: 14.28 0.51 3.70

Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing RESEARCH TRIANGLE PARK, N.C. / Jul 29, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that...Read more


Rapid Dose Therapeutics and Eco Canadian Organic Initiate Health Canada Funded SUAP Harm Reduction Pilot Project on First Nations Using QuickStrip(TM) to Combat Opiate Addiction Crisis

July 29
Last Trade: 0.19 0.005 2.78

Burlington, Ontario--(Newsfile Corp. - July 29, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotechnology company, is proud to announce the launch of a new significant harm reduction initiative aimed at addressing the devastating opioid crisis gripping Canada's First Nations communities. In collaboration with RDT and Eco Canadian Organic Inc. (ECO), a leading expert in opioid...Read more


Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders

July 28
Last Trade: 2.14 0.04 1.90

FREEHOLD, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that its subsidiary, Q&A Distribution, LLC, has entered into a wholesale distribution agreement with Saga Health Corporation (“Saga Health”) for its use of the KetoAir™ breathalyzer device in its first responder-targeted Holistic Health Reset...Read more


NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01

July 28
Last Trade: 1.70 -0.04 -2.30

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under...Read more


Talkspace Announces New In-Network Partnership with Blue Cross of Idaho

July 28
Last Trade: 2.80 0.08 2.94

Blue Cross of Idaho Members Across All Lines of Business Now Have Access to High-Quality Tele-Mental Healthcare NEW YORK / Jul 28, 2025 / Business Wire / Talkspace, a leading online behavioral health company, today announced a new in-network partnership with Blue Cross of Idaho to increase behavioral health access across Idaho. As of July 1, 2025, all Blue Cross Idaho members now have access to Talkspace’s comprehensive virtual...Read more


Pfizer Completes Licensing Agreement with 3SBio

July 24
Last Trade: 25.91 0.17 0.66

Exclusive license to promising investigational cancer immunotherapy complements and strengthens Pfizer’s innovative Oncology portfolio NEW YORK / Jul 24, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody...Read more


ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China

July 23
Last Trade: 18.95 0.02 0.11

Strategic Partnership Provides Market Presence in Growing Chinese Market PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd. (“Osstem Implant”), a leading dental solutions provider specializing in high-quality implants and integrated dental technologies...Read more


Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

July 23
Last Trade: 3.03 0.21 7.45

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has...Read more


AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

July 23
Last Trade: 1.15 0.04 3.60

DNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease Startup activities underway for Phase 1 first in human study for oral AN2-502998; Phase 2 study initiation planned for 2026 Chagas disease is a life-threatening disease that affects 6 to 7 million people worldwide, including an estimated...Read more


Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

July 22
Last Trade: 1.30 0.01 0.78

NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver...Read more


Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts

July 22
Last Trade: 25.84 0.45 1.77

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market...Read more


Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 22
Last Trade: 0.86 0.01 1.23

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug...Read more


NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan

July 17
Last Trade: 0.13 0.00 0.00

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell therapy, troculeucel, in Japan. Under Japan’s Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class...Read more


10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

July 17
Last Trade: 14.30 1.20 9.16

Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target Inference from Spatialomics...Read more


Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17
Last Trade: 20.32 0.74 3.78

NEW YORK & CAMBRIDGE, Mass. / Jul 17, 2025 / Business Wire / Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established in 2019 with a goal of leveraging Schrödinger’s advanced computational platform and Ajax’s structural biology insights to develop a pipeline of novel molecules, with a...Read more


60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

July 17
Last Trade: 1.26 -0.04 -3.08

Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell culture Borrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens most often present in individuals with tick-borne illness such as Lyme disease WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a...Read more


Oragenics Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

July 16
Last Trade: 1.10 0.03 2.80

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of...Read more


Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority

July 16
Last Trade: 1.48 0.01 0.68

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of the United States...Read more


Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

July 16
Last Trade: 499.99 16.23 3.35

Thermo Fisher to Acquire Sanofi’s Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for Sanofi Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers WALTHAM, Mass. / Jul 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to...Read more


Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15
Last Trade: 1.59 0.04 2.58

CAMBRIDGE, Mass. & MONTREAL / Jul 15, 2025 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. (“Debiopharm”), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious...Read more


Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

July 15
Last Trade: 0.95 0.07 7.51

TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a...Read more


Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

July 15
Last Trade: 57.09 3.09 5.72

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as...Read more


Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

July 15
Last Trade: 1.53 0.17 12.50

Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology Preclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer’s disease Agreement follows more than one year of engagement to assess technical...Read more


VentriPoint Diagnostics and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology

July 11
Last Trade: 0.11 0.00 0.00

Toronto, Ontario – TheNewswire - July 11, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman’s echocardiography image platform in the People’s Republic of China including the Special Administrative Regions of Hong Kong...Read more


Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

July 10
Last Trade: 23.53 0.40 1.73

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced a new partnership with ŌURA, maker of the world’s leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team...Read more


AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

July 10
Last Trade: 210.60 1.10 0.53

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's...Read more


Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

July 9
Last Trade: 4.83 0.17 3.65

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types FREMONT, Calif. / Jul 09, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and...Read more


Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

July 9
Last Trade: 0.18 -0.02 -7.69

Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) to evaluate Eledon’s...Read more


Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

July 9
Last Trade: 3.79 0.18 4.99

Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain management. FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing...Read more


Gilead Sciences Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

July 9
Last Trade: 114.77 -1.37 -1.18

Strategic Partnership Agreement is Part of Gilead’s Commitment to Provide Lenacapavir at No Profit in High-Incidence, Resource-Limited Countries Until Licensed Generics Can Fully Meet Demand  FOSTER CITY, Calif. / Jul 09, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply...Read more


Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

July 9
Last Trade: 37.01 0.53 1.45

Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines’ access to Iambic’s industry-leading NeuralPLexer model for protein structure prediction REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE...Read more


Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

July 8
Last Trade: 7.83 0.00 0.00

Collaboration builds on years of joint research, additional patent applications, and data from several clinical trials to accelerate therapeutic innovation in neurodegeneration LOS ANGELES / Jul 08, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a...Read more


Certara Announces Expansion of Clinical Technology Collaboration with Merck

July 8
Last Trade: 11.47 0.70 6.50

Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to...Read more


Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

July 8
Last Trade: 2.39 0.11 4.82

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner...Read more


LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

July 7
Last Trade: 40.00 0.15 0.38

Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada....Read more


Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico

July 3
Last Trade: 25.60 0.35 1.39

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the...Read more


Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

July 2
Last Trade: 0.52 -0.0079 -1.50

SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David Putrino are key thought leaders in the clinical and translational biology of Long COVID and Post-Vaccination Syndrome Initial SPEAR clinical efforts to be aimed at rigorous, controlled...Read more


Nano-X Imaging Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC

July 1
Last Trade: 4.06 0.05 1.25

Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technology Clinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH TIKVA, Israel, July 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced a clinical and educational collaboration with Keiser...Read more


Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

July 1
Last Trade: 13.00 0.37 2.93

SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive’s...Read more


Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 1
Last Trade: 5.47 -0.28 -4.88

Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule  Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025  Torii to fund the first $40 million of out-of-pocket costs for the global study, representing...Read more


Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 30
Last Trade: 37.01 0.53 1.45

REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious...Read more


RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening

June 27
Last Trade: 3.54 0.00 0.00

Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early...Read more


Ainos and ASE Technology Broaden Strategic Partnership to Target Deploy Up to 15,000 AI Nose Across Key Sites

June 27
Last Trade: 3.56 0.10 2.89

Relationship Broadens Scope to Key ASE and SPIL Facilities with Multi-Phase Deployment Milestone Positions ASEH and Ainos as First-Mover in AI-Powered Scent Intelligence for the Semiconductor Industry SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 27, 2025 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ("Ainos" or the "Company") , a leader in AI-driven scent digitization, today announced the expansion of its strategic relationship with...Read more


Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

June 26
Last Trade: 2.92 0.03 1.04

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company...Read more


Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

June 26
Last Trade: 56.93 1.48 2.67

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new...Read more


DarioHealth and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

June 26
Last Trade: 0.57 0.02 3.64

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in...Read more


Avalon GloboCare and Qi Diagnostics Enter into Definitive Agreement to Co-Develop Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

June 26
Last Trade: 2.14 0.04 1.90

FREEHOLD, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it entered into a definitive agreement with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. Through...Read more


KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

June 26
Last Trade: 13.41 0.45 3.47

Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic areas with capabilities to launch sebetralstat in Canadian market CAMBRIDGE, Mass. & SALISBURY, England / Jun 26, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista...Read more


PureTech Health Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

June 26
Last Trade: 19.00 0.60 3.26

BOSTON / Jun 26, 2025 / Business Wire / PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) announced entry into an...Read more


Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 25
Last Trade: 2.17 -0.02 -0.91

Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties Seasoned biopharma...Read more


Veeva Systems and AWS Expand 10-Year Relationship

June 25
Last Trade: 290.86 8.58 3.04

AWS compute, database, and global infrastructure support Veeva’s industry cloud for life sciences PLEASANTON, Calif. & SEATTLE / Jun 25, 2025 / Business Wire / Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and Veeva Systems (NYSE: VEEV), a leading provider of software, data, and business consulting for the life sciences industry, today announced an expansion of their long-standing collaboration. Veeva...Read more


Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

June 25
Last Trade: 0.63 -0.04 -5.45

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics,...Read more


Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

June 25
Last Trade: 0.38 0.0079 2.12

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a...Read more


Hoth Therapeutics and Silo Pharma today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty live

June 25
Last Trade: 1.30 0.01 0.78

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to...Read more


Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

June 25
Last Trade: 114.77 -1.37 -1.18

FOSTER CITY, Calif. & WATERTOWN, Mass. / Jun 25, 2025 / Business Wire / Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in...Read more


Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

June 25
Last Trade: 3.64 0.10 2.82

NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI. This partnership will enable...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE